

**REPORT No. 978975-1/25/SLV/GDA/PK**

|                                                                                |            |                                                                 |
|--------------------------------------------------------------------------------|------------|-----------------------------------------------------------------|
| Sponsor                                                                        |            | Sample according to declaration of Client                       |
| <b>BTI KI TRENING D.O.O.<br/>NOVI SVET 6<br/>4220 ŠKOFJA LOKA<br/>SLOVENIA</b> |            | <b>MOUNTAINDROP HIMALAYAN<br/>SHILAJIT 100G</b>                 |
| Sample reception date:                                                         | 05.12.2025 | Sample status: no objections<br>Sample received from the Client |
| Start of the study:                                                            | 12.01.2026 |                                                                 |
| End of the study                                                               | 15.04.2026 |                                                                 |
| Report date:                                                                   | 24.04.2026 |                                                                 |

**REPORT OF USE TEST AND INSTRUMENTAL TEST  
UNDER INTERNIST SUPERVISION**

**CONTENT OF THE REPORT**

|         |                                                                                     |    |
|---------|-------------------------------------------------------------------------------------|----|
| 1.      | INITIAL REPORT DESIGN.....                                                          | 4  |
| 1.1     | Study objectives.....                                                               | 4  |
| 1.2     | Ethical conduct of the study.....                                                   | 4  |
| 1.3     | Quality control .....                                                               | 4  |
| 1.4     | Relevance of the study .....                                                        | 5  |
| 1.5     | Ethical committee.....                                                              | 5  |
| 1.6     | Information of the test subject and informed consent form .....                     | 6  |
| 1.7     | Confidentiality of the subject .....                                                | 6  |
| 1.8     | The basis to conduct the study .....                                                | 7  |
| 2.      | INVESTIGATIONAL PRODUCT .....                                                       | 8  |
| 2.1     | Description of the product .....                                                    | 8  |
| 3.      | STUDY DESCRIPTION.....                                                              | 8  |
| 3.1     | Aim of the study.....                                                               | 8  |
| 3.2     | General principle of the study .....                                                | 8  |
| 3.3     | TESTING METHODOLOGY .....                                                           | 9  |
| 3.3.1   | Use test .....                                                                      | 9  |
| 3.3.2   | Internist evaluation .....                                                          | 9  |
| 3.3.3   | Instrumental test .....                                                             | 10 |
| 3.3.3.1 | Instrumental test of biomechanical skin parameter by using Cutometer® MPA 580.....  | 10 |
| 3.3.3.2 | Instrumental test of hair density using Aramo ASW® 300F .....                       | 10 |
| 3.4     | Suspension of the study .....                                                       | 10 |
| 3.5     | Adverse events .....                                                                | 10 |
| 3.6     | Raw data recording.....                                                             | 11 |
| 4.      | DESCRIPTION OF SUBJECTS .....                                                       | 12 |
| 5.      | TRIAL SCHEDULE .....                                                                | 14 |
| 6.      | RESULTS .....                                                                       | 15 |
| 6.1     | Characteristic of subjects .....                                                    | 15 |
| 6.2     | Assessment of the product impact on tolerance (regular application) .....           | 16 |
| 6.3     | Confirmation of the effect claimed for the cosmetic product .....                   | 19 |
| 6.4     | Instrumental test results .....                                                     | 20 |
| 6.4.1   | Instrumental test of biomechanical skin parameter by using Cutometer® MPA 580 ..... | 20 |
| 6.4.2   | Instrumental test of hair density using Aramo ASW® 300F.....                        | 22 |
| 7.      | CONCLUSION.....                                                                     | 23 |
| 8.      | APPENDIX .....                                                                      | 24 |
| 8.1     | Internist's scores – individual results .....                                       | 24 |
| 8.2     | Summary of the questionnaire .....                                                  | 25 |
| 9.      | SIGNATURES .....                                                                    | 26 |

**STUDY REFERENCE**

|                            |                                                                                          |
|----------------------------|------------------------------------------------------------------------------------------|
| SPONSOR                    | <b>BTI KI TRENING D.O.O.</b><br>NOVI SVET 6<br>4220 ŠKOFJA LOKA<br>SLOVENIA              |
| STUDY MONITOR              | Peter Babarović                                                                          |
| INVESTIGATING CENTRE       | <b>J.S. HAMILTON POLAND SP. Z O.O.</b><br>BAJANA 3D<br>80-463 GDAŃSK<br>POLAND           |
| PROJECT MANAGER            | Marta Sadowska                                                                           |
| MAIN INVESTIGATOR          | <b>Dorota Polańska - Tamborek</b><br>(Internal Medicine Doctor)<br>Registered N° 1175865 |
| ETHICAL COMMITTEE APPROVAL | 09.01.2026                                                                               |

## **1. INITIAL REPORT DESIGN**

### **1.1 Study objectives**

This study intended to check the tolerance and efficacy of the investigational product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** in a panel of healthy human subject after use under normal condition.

### **1.2 Ethical conduct of the study**

The described study was conducted in the spirit of the Good Clinical Practice defined by the ICH Topic E6 "Note for Guidance and good clinical practice" (CPMP/ICH/135/95), the Helsinki Declaration (1964, WMA) and its successive updates. The study was conducted according to Standard Operating Procedures and to the study protocol defined by the sponsor. All study events recorded during the study was reported. Controls on data veracity and conformity with the protocol was performed and confirmed by persons participating in the study.

SCOPE OF TESTS COMPLIANT WITH:

- Regulation of the European Parliament and of the Council (EC) No. 1223/2009 of 30 November 2009 on cosmetic products.
- Cosmetics Europe – The Personal Care Association (previously COLIPA) Guidelines "Product Test Guidelines for the Assessment of Human Skin Compatibility 1997."
- Cosmetics Europe – The Personal Care Association (previously COLIPA) Guidelines for the Evaluation of the Efficacy of Cosmetic Products 2008.
- Cosmetics Europe - The Personal Care Association (previously COLIPA) GUIDELINES FOR COSMETIC PRODUCT CLAIM SUBSTANTIATION Revising and expanding the Colipa Guidelines on Efficacy (2001/rev. 2008) 22 May 2019.

### **1.3 Quality control**

The study was performed in compliance with the procedures of the investigating centre, established according to the regulations in force.

The investigator, in charge of the performance of the study, made sure of the quality of the work of the technical staff, particularly concerning the respect of the protocol and its appendices, the collection of raw data, the management of the investigational product.

#### **1.4 Relevance of the study**

Based on the existing data, the main aim of the study being a better knowledge of the tolerance and effectiveness of the investigational product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G**. This product will be used under normal conditions, the foreseeable risk incurred by the test subjects will be minor. So, there will be suitability between the aim of the study and its eventual risks and the foreseeable troubles related to the experimental conditions of the protocol.

The experimental conditions adopted for the tested formula **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** (method of use, amount of test product used, frequency of use...) was reproduced the normal conditions of use. The observance of the experimental conditions by the test subjects was assessed at the end of the study. The test subjects opinion was taken into account since it should reflect that of the potential consumers.

The examination was performed by the internist having an appropriate experience.

#### **1.5 Ethical committee**

According to the procedure of investigating centre, the protocol, the informed consent form and the preclinical information concerning the investigational product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** was submitted to the internal committee of the investigating centre.

The committee got sure that the project meets the conditions of optimal scientific rigor, assessed its general relevance, the suitability between the aim followed and the means implemented and gave an opinion on the protection of the test subjects.

The study does not begin without the approval of the Survey committee.

**1.6 Information of the test subject and informed consent form**

The information about the study was given orally and as a written document to each test subject before the start of the study. This information is accessible, understandable and suitable for each test subject. This information was completed, if necessary, by the investigator (or the competent person designated) who answered all the questions asked by the test subject.

The content of this document particularly specified:

- the aim of the study,
- the study design and the experimental conditions of the study,
- the approximate number of test subjects involved in the study,
- the expected duration of the study (for the test subject),
- the number of visits to the investigating centre, their dates and their duration,
- the study constraints (obligations, restrictions and troubles),
- that skin site photographs can be taken and in this case, that the test subject would not be recognizable,
- the opinion of the internal committee,
- the person to contact and the contact telephone number,
- that the personal data of the test subject would be confidentially treated by the study staff, available for the study monitor and possibly consulted (with the authorization of the test subject) by the auditors and the members of the internal committee,
- the ban on taking part simultaneously in other clinical studies,
- the amount of the compensation for the constraints to be undergone,
- the period of exclusion at the end of the study during which the test subject would not be allowed to take part in another clinical study,
- the confidential treatment of the study data,
- that the anonymity of the test subject was preserved,
- the freedom for the test subject to refuse to participate or to stop his participation at any time without any justification and any legal consequences.

At the beginning of the study, two copies of this document was dated and signed simultaneously by the test subject and by the investigator or the competent person designated. One copy was given to the test subject, the other was kept at the investigating center.

**1.7 Confidentiality of the subject**

The information concerning the subject, required for his recruitment, inclusion and particularly that related to his health, obtained during the medical examination, formed part of medical secret and was confidentially treated.

The test subject was coded when included in the study to preserve his anonymity.

**1.8 The basis to conduct the study**

- Samples delivered by the Sponsor.
- The qualitative composition of the product delivered by the Sponsor.

The Sponsor is responsible for conformity with the declared quality composition of the products.

## 2. INVESTIGATIONAL PRODUCT

### 2.1 Description of the product

| Parameter          | Description                                                                                                                                                                                                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Products reference | MOUNTAINDROP HIMALAYAN SHILAJIT 100G                                                                                                                                                                                          |
| Intended use       | The product is intended for supplementation.                                                                                                                                                                                  |
| Method of use      | Mix in to an aprox. 2dl warm water until dissolved completely. After that, drink it. Once daily in the morning before breakfast. We advise they use the provided measuring spoon to scoop out 0.3g to 0.4g of Shilajit daily. |

Contraindications for use of the product is: allergy recognized or hypersensitivity to any of its ingredients.

## 3. STUDY DESCRIPTION

### 3.1 Aim of the study

The aim of the study was to determine tolerance, confirm/exclude of the declared product properties and to evaluate the direct influence of the investigational product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** on improving in skin firmness and elasticity and hair density 90 consecutive days of use.

### 3.2 General principle of the study

The investigational product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** was used according to the method of use by the subjects at home. The test subject was used as own control.

### **3.3 TESTING METHODOLOGY**

#### **3.3.1 Use test**

The use test was performed at home under internist supervision. The study concerned on:

- assessment of the product's impact on skin condition as a result of regular, repeated use of the tested product, in accordance with its intended purpose and method of use within a specified period of time (repetitive test).
  - a skin examination performed by a technician or an investigator before using the product and after the period of use,
  - analysis of feelings of discomfort reported directly by the subjects to the investigator during the study or in daily log.

#### **3.3.2 Internist evaluation**

The medical interview by internist was collected before the product application and after 90 days of use.

The internist using a 5 point structured scale from 0 to 4 asked subjects about the symptoms.

|                         | <b>None<br/>(0)</b> | <b>Mild<br/>(1)</b> | <b>Moderate<br/>(2)</b> | <b>Severe<br/>(3)</b> | <b>Extremely<br/>severe (4)</b> |
|-------------------------|---------------------|---------------------|-------------------------|-----------------------|---------------------------------|
| General health issues.  |                     |                     |                         |                       |                                 |
| Mild or severe fatigue. |                     |                     |                         |                       |                                 |
| Digestive problems.     |                     |                     |                         |                       |                                 |
| Slowed metabolism.      |                     |                     |                         |                       |                                 |

- research leading to confirm or exclude the properties claimed for the product.

The Evaluation Questionnaire form, the characteristic of the panel and number of subjects were in line with Sponsor requirements. The product was used by subjects accordance with the declared method of use.

**Declarations will be confirmed only if the ratio of the received positive responses to the total number of subjects participating in the study will be above 50%.**

### **3.3.3 Instrumental test**

#### **3.3.3.1 Instrumental test of biomechanical skin parameter by using Cutometer® MPA 580**

The aim of the test was to define the direct influence of the tested product on biomechanical skin parameter (skin firmness and elasticity) by using Cutometer® MPA 580. The test has been conducted using special measuring device manufactured by Courage + Khazaka Company. Instrumental study has been carried out on 27 subjects. The measurements have been performed at the specified zone – before using the product (D0) and after 90 days (D90) of regular use. The study has been carried out in an air conditioned room in the temp. of  $20\pm 2^{\circ}\text{C}$  and relative humidity  $50\pm 10\%$ . The product efficacy is confirmed in case of the positive results obtained in more than 50% of subjects.

#### **3.3.3.2 Instrumental test of hair density using Aramo ASW® 300F**

The aim of the study was to assess the direct impact of the tested product on hair density. The test has been conducted using special measuring device manufactured by ARAM HUVIS Co., Ltd. – ARAMO ASW® 300F. Instrumental study has been carried out on 27 subjects. The measurements in zoom 60-times has been performed at the specified zone - before using the product (D0) after 90 days (D90) of regular use. The study has been carried out in an air conditioned room in the temp. of  $20\pm 2^{\circ}\text{C}$  and relative humidity  $50\pm 10\%$ . The product efficacy is confirmed in case of the positive results obtained in more than 50% of subjects.

### **3.4 Suspension of the study**

The investigator has to stop the study if it shows a risk for the health or the integrity of the test subjects. The date of the suspension and the reasons has to be carefully documented by the investigator in the case report form (CRF).

The investigating centre has to inform promptly the study monitor, by phone, fax or e-mail. The sponsor was able to stop the study at any time for administrative reasons or other ones.

### **3.5 Adverse events**

According to individual sensitivities, any product can induce a minor reactivity, defined as follows: any slight local reaction of intolerance or sensation of discomfort, occurring in a test subject during a clinical study, completely reversible, expected, due to the investigational product and which does not question the observance of the study protocol or the good implementation of the study.

- **adverse event:** any harmful event with or without relationship with the investigational product, occurring in a test subject during a clinical study.

- **serious adverse event:** any adverse event that causes death, endangers test subject's life, induces an hospitalization or the prolongation of the hospitalization, causes severe and lasting incapacity or handicap or induces congenital anomaly or malformation.

The investigator has to accurately describe the adverse event and has to appreciate its seriousness. According to the corresponding procedure of the investigating centre, he has to define the link of causality between this event and the investigational product, on the basis of the symptoms, the chronology, the results of the possible specific complementary tests undertaken and any available information.

The imputability of the investigational product has to be assessed according to the scale: very likely, likely, possible, questionable, excluded. In case of adverse effect (with a quite possible relationship with the investigational product), the investigator has to ensure the clinical follow-up of the test subject concerned, as long as necessary.

The serious adverse events has to be notified as soon as possible and within 24 hours at the latest, by the investigating centre to the study monitor, by phone, fax or e-mail. The investigator has to send an adverse event form to the study monitor.

### **3.6 Raw data recording**

All the data gathered during the study was recorded accurately, legibly and indelibly by the investigator and the technician in charge of the study, under his control, in the case report form. This document was initialed by the technician or investigator.

At the end of the study, the information concerning the investigational product, the information concerning the test subjects (CRF(s), daily logs, informed consent forms) and the information related to the conduct of the study (protocol signed by the sponsor, copy of this study report....) were filed in the filing area of the investigating centre.

#### 4. DESCRIPTION OF SUBJECTS

|                                    |                                                                                                                                                                                                                                                                                                   |                         |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| <b>GENERAL INCLUSION CRITERIA</b>  | Healthy subject.                                                                                                                                                                                                                                                                                  |                         |
|                                    | Sign an informed consent to participate in the study, were informed about the purpose of the study, the manner of its conduct and the possible side effects.                                                                                                                                      |                         |
|                                    | Skin without irritation and changes requiring pharmacological treatment.                                                                                                                                                                                                                          |                         |
|                                    | Phototype: I – IV on Fitzpatrick scale.                                                                                                                                                                                                                                                           |                         |
|                                    | Cooperative subject, aware of the necessity and duration of controls.                                                                                                                                                                                                                             |                         |
| <b>SPECIFIC INCLUSION CRITERIA</b> | Amount of subjects:                                                                                                                                                                                                                                                                               | 33 subjects             |
|                                    | Gender:                                                                                                                                                                                                                                                                                           | 7 women<br>16 men       |
|                                    | Age:                                                                                                                                                                                                                                                                                              | 25-50                   |
|                                    | Face skin type:                                                                                                                                                                                                                                                                                   | All, 100% non-sensitive |
|                                    | Body skin type:                                                                                                                                                                                                                                                                                   | All, 100% non-sensitive |
|                                    | Hair type:                                                                                                                                                                                                                                                                                        | All                     |
|                                    | Scalp type:                                                                                                                                                                                                                                                                                       | All, 100% non-sensitive |
| <b>NON INCLUSION CRITERIA</b>      | Subject with allergies or other contraindications to any compound present in the supplement.                                                                                                                                                                                                      |                         |
|                                    | The subject was taking medications (corticosteroids, indomethacin, glucosamine + chondroitin), in the 3 months prior to the study.                                                                                                                                                                |                         |
|                                    | The subject is taking supplements that may affect the test results (collagen, hyaluronan, glucosamine, hondroitin, elastin, methylsulfonylmethane (MSM), concentrated plant extracts, vitamin C, E, D supplements, other specific supplements to support metabolism, concentration and energies). |                         |
|                                    | The subject suffers from severe diseases (e.g., cardiovascular, liver, kidney, gastrointestinal, metabolic or autoimmune) or systemic joint or muscle diseases (e.g., rheumatoid arthritis), diseases affecting protein absorption.                                                               |                         |
|                                    | The subject has gallstone problems.                                                                                                                                                                                                                                                               |                         |
|                                    | The subject with a history of mental disorders that may impair the subjects' ability to give informed written consent.                                                                                                                                                                            |                         |
|                                    | The subject exhibiting or having a history of acute or chronic medical and/or physical conditions that may affect the outcome of this study.                                                                                                                                                      |                         |
|                                    | The subject is abusing alcohol and/or psychoactive and addictive substances.                                                                                                                                                                                                                      |                         |
|                                    | The subject treated with sympathomimetics, antihistamines, nonsteroidal anti-inflammatory drugs, and/or other drugs that may have influenced the results of this study, within one week prior to initiation of this study.                                                                        |                         |
|                                    | A woman who is pregnant or breastfeeding or planning a pregnancy during the examination.                                                                                                                                                                                                          |                         |
|                                    | The subject is participating in another clinical trial at the same time.                                                                                                                                                                                                                          |                         |
|                                    | Subject with androgene baldness.                                                                                                                                                                                                                                                                  |                         |

|                             |                                                                                                                                                                                                        |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             | The subject, in the opinion of the investigator, may not follow the requirements of the protocol.                                                                                                      |
| <b>INFORMED<br/>CONSENT</b> | After an explanation of the protocol, reasons for the study, possible associated risks and potential benefits of the treatment each subject signed an informed consent form before starting the study. |

The qualified subjects received the tested product, specially developed questionnaire, the daily log and were obliged to:

- use of the product according to the method of use,
- during the test any other products of similar effects must not be used,
- a detailed evaluation of the tested product by using the received questionnaire,
- in case of discomfort or any medicine taken fill the daily log,
- in case of any side effects on skin they should immediately stop using the product and consult investigator at J.S. Hamilton Poland.

Skin reactivity, history of atopy and contraception were documented by the investigator, in the case report form (CRF). No medication likely to interfere with the study was allowed during the study; however, if the health state of the subjects justifies some medication (particularly anti-inflammatory drugs), any information relating to this concomitant medication had to be carefully documented in the case report form. The investigator had to exclude the test subjects taking concomitant medication likely to interfere with the study and the interpretation of the results.

The test results may be affected by such factors as:

- the skin condition,
- inter-individual genetic characteristics,
- individual preferences of subjects.

**5. TRIAL SCHEDULE**

D0:

- Subjects came to the laboratory.
- Subjects signed informed consent forms in duplicate.
- Verification of inclusion and non-inclusion criteria.
- The internist examines subjects to assess issues.
- The trained technician determined and examined the study zones.
- The measurements of the studied zone:
  - Instrumental test of biomechanical skin parameters,
  - Measurement of hair density,
- Distribution studied product, questionnaire and daily log. Each subject is instructed to use the tested product as described in daily log and record the dates of use.

D90:

- The subjects come to the laboratory.
- Collecting and checking the daily log in case of adverse events.
- The internist examines patients to assess issues.
- The trained technician examined the study zones.
- The measurements of the studied zone:
  - Instrumental test of biomechanical parameters,
  - Measurement of hair density,
- Collecting questionnaire.
- Record of possible adverse reactions.

## 6. RESULTS

### 6.1 Characteristic of subjects

| Subject's no. | Subject's code | Gender | Age   | Body skin type | Body skin sensitivity | Face skin type | Face skin sensitivity | Scalp type | Scalp sensitivity | Hair type | Instrumental study | Study initiation date | Study completion date                    | Comments                                              |
|---------------|----------------|--------|-------|----------------|-----------------------|----------------|-----------------------|------------|-------------------|-----------|--------------------|-----------------------|------------------------------------------|-------------------------------------------------------|
| 1.            | PRA OL         | W      | 28    | N              | N                     | C              | N                     | D          | N                 | D         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 2.            | BAB KR         | M      | 27    | N              | N                     | N              | N                     | N          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| (1,3)*        | (KAP JU)*      | (W)*   | (25)* | (N)*           | (N)*                  | (C)*           | (N)*                  | (N)*       | (N)*              | (N)*      | (Y)*               | 12.01.2026            | (The subject did not finish the study.)* | -                                                     |
| 4.            | SZY DO         | W      | 26    | N              | N                     | C              | N                     | N          | N                 | G         | Y                  | 12.01.2026            | 13.04.2026                               | -                                                     |
| 5.            | GOL DA         | M      | 25    | N              | N                     | C              | N                     | N          | N                 | D         | Y                  | 12.01.2026            | 15.04.2026                               | The subject finished the study on D93 instead of D90. |
| 6.            | MAR AL         | W      | 26    | N              | N                     | C              | N                     | O          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 7.            | KRA AN         | W      | 30    | N              | N                     | C              | N                     | N          | N                 | G         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 8.            | WOZ MA         | W      | 27    | N              | N                     | C              | N                     | D          | N                 | D         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 9.            | LP KL          | W      | 26    | N              | N                     | N              | N                     | N          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 10.           | CE KA          | W      | 28    | N              | N                     | C              | N                     | O          | N                 | G         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| (11,)*        | (ZYW MD)*      | (W)*   | (27)* | (N)*           | (N)*                  | (C)*           | (N)*                  | (N)*       | (N)*              | (D)*      | (Y)*               | 12.01.2026            | (The subject did not finish the study.)* | -                                                     |
| 12.           | MDK PA         | W      | 25    | N              | N                     | O              | N                     | O          | N                 | D         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 13.           | FRA DA         | W      | 30    | D              | N                     | D              | N                     | D          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 14.           | HOB AL         | W      | 26    | D              | N                     | O              | N                     | O          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 15.           | KON PA         | M      | 30    | N              | N                     | C              | N                     | O          | N                 | G         | Y                  | 12.01.2026            | 15.04.2026                               | The subject finished the study on D93 instead of D90. |
| 16.           | ZBI RO         | W      | 27    | N              | N                     | D              | N                     | N          | N                 | G         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 17.           | MDK PA         | W      | 25    | N              | N                     | C              | N                     | N          | N                 | G         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| (18,)*        | (WOJ AN)*      | (W)*   | (26)* | (N)*           | (N)*                  | (N)*           | (N)*                  | (N)*       | (N)*              | (N)*      | (Y)*               | 12.01.2026            | (The subject did not finish the study.)* | -                                                     |
| 19.           | KOS TO         | M      | 30    | D              | N                     | D              | N                     | D          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 20.           | STA MD         | W      | 28    | N              | N                     | C              | N                     | N          | N                 | G         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 21.           | GAW MA         | M      | 26    | N              | N                     | C              | N                     | N          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 22.           | REY ST         | M      | 25    | N              | N                     | N              | N                     | N          | N                 | G         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 23.           | ADA NI         | M      | 28    | N              | N                     | N              | N                     | N          | N                 | N         | Y                  | 12.01.2026            | 15.04.2026                               | The subject finished the study on D93 instead of D90. |
| 24.           | ZAW MA         | M      | 30    | N              | N                     | N              | N                     | N          | N                 | N         | Y                  | 12.01.2026            | 15.04.2026                               | The subject finished the study on D93 instead of D90. |
| 25.           | LAW MA         | M      | 29    | D              | N                     | D              | N                     | D          | N                 | D         | Y                  | 12.01.2026            | 13.04.2026                               | The subject did not finish the instrumental study.    |
| 26.           | DZI SE         | M      | 29    | N              | N                     | N              | N                     | N          | N                 | N         | Y                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 27.           | ADA EL         | W      | 27    | D              | N                     | D              | N                     | O          | N                 | G         | Y                  | 12.01.2026            | 15.04.2026                               | The subject finished the study on D93 instead of D90. |
| 28.           | KRE LU         | M      | 27    | N              | N                     | N              | N                     | N          | N                 | N         | N                  | 12.01.2026            | 13.04.2026                               | -                                                     |
| 29.           | LAW JA         | M      | 27    | D              | N                     | N              | N                     | N          | N                 | N         | N                  | 12.01.2026            | 14.04.2026                               | -                                                     |
| 30.           | BIA KA         | M      | 28    | N              | N                     | C              | N                     | N          | N                 | N         | N                  | 12.01.2026            | 13.04.2026                               | -                                                     |
| 31.           | RDS BA         | M      | 26    | N              | N                     | N              | N                     | D          | N                 | G         | N                  | 12.01.2026            | 13.04.2026                               | -                                                     |
| 32.           | SZY PJ         | M      | 27    | N              | N                     | N              | N                     | N          | N                 | G         | N                  | 12.01.2026            | 13.04.2026                               | -                                                     |
| 33.           | MAR MA         | W      | 25    | D              | N                     | D              | N                     | N          | N                 | N         | N                  | 12.01.2026            | 13.04.2026                               | -                                                     |

|           |    |         |    |      |    |     |    |     |    |         |   |         |   |        |    |                 |    |          |   |         |   |         |   |        |    |         |   |         |   |        |    |         |   |         |    |                                           |    |                                            |    |
|-----------|----|---------|----|------|----|-----|----|-----|----|---------|---|---------|---|--------|----|-----------------|----|----------|---|---------|---|---------|---|--------|----|---------|---|---------|---|--------|----|---------|---|---------|----|-------------------------------------------|----|--------------------------------------------|----|
| WOMAN (W) | 15 | MAN (M) | 15 | MEAN | 27 | MIN | 25 | MAX | 30 | DRY (D) | 7 | YES (Y) | 8 | NO (N) | 30 | COMBINATION (C) | 12 | ONLY (O) | 2 | DRY (D) | 6 | YES (Y) | 0 | NO (N) | 30 | DRY (D) | 6 | YES (Y) | 0 | NO (N) | 30 | DRY (D) | 5 | YES (Y) | 24 | NUMBER OF SUBJECTS, WHO STARTED THE STUDY | 33 | NUMBER OF SUBJECTS, WHO FINISHED THE STUDY | 30 |
|-----------|----|---------|----|------|----|-----|----|-----|----|---------|---|---------|---|--------|----|-----------------|----|----------|---|---------|---|---------|---|--------|----|---------|---|---------|---|--------|----|---------|---|---------|----|-------------------------------------------|----|--------------------------------------------|----|

#### Legend:

()\* - The subject was not included in the calculation.

## 6.2 Assessment of the product impact on tolerance (regular application)

On the basis of medical examinations and interviews collected from subjects we found that the tested product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** was very well tolerated. For the most part of subjects, who finished the study, after regular use of the product, in the interview there was no negative symptoms or sensations that could indicate intolerance to any of the product ingredients, i.e. redness, burning, swelling, tingling sensations and itching.

**The results obtained in the test allow to conclude, that the product used as intended is very well tolerated by the people, in whom there is not a contraindication to its use.**

Table 1. Medications taken by the subjects during the study.

| Subject's no. | Name          | Indication | Duration                   |
|---------------|---------------|------------|----------------------------|
| 2.            | Apap®         | Headache   | 7 days (D6-D10, D45, D55)  |
|               | Nimesil®      | Headache   | 2 days (D9-D10)            |
|               | Efferalgan®   | Headache   | 2 days (D67, D86)          |
| 10.           | Ibuprofen     | Headache   | 3 days (D52, D55, D77)     |
|               | Gripex®       | Sinusitis  | 9 days (D54, D57, D77-D83) |
|               | Xylometazolin | Sinusitis  | 7 days (D77-D83)           |
|               | Metmin®       | Sinusitis  | 6 days (D84-D89)           |

Table 2. Summary of subjective evaluations.

| Subject's no. | Subjective Evaluations<br>(as reported in daily logs)                  |
|---------------|------------------------------------------------------------------------|
| 1.            | No reaction                                                            |
| 2.            | No reaction                                                            |
| 3.            | Untraceable                                                            |
| 4.            | No reaction                                                            |
| 5.            | No reaction                                                            |
| 6.            | No reaction                                                            |
| 7.            | No reaction                                                            |
| 8.            | No reaction                                                            |
| 9.            | No reaction                                                            |
| 10.           | No reaction                                                            |
| 11.           | Untraceable                                                            |
| 12.           | No reaction                                                            |
| 13.           | Mild general health issues.                                            |
| 14.           | No reaction                                                            |
| 15.           | No reaction                                                            |
| 16.           | No reaction                                                            |
| 17.           | No reaction                                                            |
| 18.           | Untraceable                                                            |
| 19.           | Mild general health issues, moderate fatigue, mild digestive problems. |
| 20.           | No reaction                                                            |
| 21.           | No reaction                                                            |
| 22.           | No reaction                                                            |
| 23.           | No reaction                                                            |
| 24.           | No reaction                                                            |
| 25.           | No reaction                                                            |
| 26.           | No reaction                                                            |
| 27.           | Mild general health issues.                                            |
| 28.           | No reaction                                                            |
| 29.           | Mild general health issues, moderate fatigue.                          |
| 30.           | No reaction                                                            |
| 31.           | No reaction                                                            |
| 32.           | Moderate general health issues.                                        |
| 33.           | Mild fatigue.                                                          |

Table 3. Summary of internist's evaluation

| Internist's evaluation <input type="checkbox"/>           |                       |             |                        |             |                    |             |                   |             |
|-----------------------------------------------------------|-----------------------|-------------|------------------------|-------------|--------------------|-------------|-------------------|-------------|
| Evaluation of problem indicators <input type="checkbox"/> |                       |             |                        |             |                    |             |                   |             |
|                                                           | General health issues |             | Mild or severe fatigue |             | Digestive problems |             | Slowed metabolism |             |
|                                                           | BEFORE (D0)           | AFTER (D90) | BEFORE (D0)            | AFTER (D90) | BEFORE (D0)        | AFTER (D90) | BEFORE (D0)       | AFTER (D90) |
| "0"                                                       | 27                    | 23          | 7                      | 11          | 16                 | 25          | 22                | 29          |
| "1"                                                       | 4                     | 6           | 15                     | 13          | 11                 | 2           | 8                 | 1           |
| "2"                                                       | 2                     | 1           | 9                      | 6           | 6                  | 2           | 3                 | 0           |
| "3"                                                       | 0                     | 0           | 2                      | 0           | 0                  | 1           | 0                 | 0           |
| "4"                                                       | 0                     | 0           | 0                      | 0           | 0                  | 0           | 0                 | 0           |

Legend:

0 – none

1 – mild

2 – moderate

3 – severe

4 – extremely severe

Individual results are presented in the Appendix **8.1**.

### 6.3 Confirmation of the effect claimed for the cosmetic product

Based on the results of use test – subjective feelings of subjects properties of product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** declared by the Client were assessed as follows:

|                                                                     |     |                    |
|---------------------------------------------------------------------|-----|--------------------|
| The product visibly improves skin elasticity.                       | 87% | positive responses |
| The product gives the feeling of hydration.                         | 77% | positive responses |
| The product reduces the appearance of wrinkles.                     | 53% | positive responses |
| The product visibly improves hair and nail growth.                  | 73% | positive responses |
| The product visibly increases hair density and nail strength.       | 87% | positive responses |
| The product visibly reduces hair loss.                              | 77% | positive responses |
| The product appears to improve physical energy.                     | 87% | positive responses |
| The product appears to reduce fatigue.                              | 87% | positive responses |
| The product appears to increase endurance.                          | 73% | positive responses |
| The product seems to improve concentrations and mental clarity.     | 80% | positive responses |
| The product seems to reduce "brain fog" (increased concentrations). | 83% | positive responses |
| The product seems to reduce stress.                                 | 80% | positive responses |
| The product seems to speed up recovery from exercise.               | 77% | positive responses |
| The product seems to improve sleep quality (I feel more rested).    | 93% | positive responses |
| The product seems to maintain good skin condition.                  | 87% | positive responses |
| The product seems to increase overall vitality.                     | 87% | positive responses |
| The product seems to improve libido.                                | 67% | positive responses |

#### Moreover:

|                                                                                         |     |                    |
|-----------------------------------------------------------------------------------------|-----|--------------------|
| Suitable appearance/functionality.                                                      | 83% | positive responses |
| Suitable consistency.                                                                   | 63% | positive responses |
| Suitable application.                                                                   | 90% | positive responses |
| Overall assessment of the product.                                                      | 70% | positive responses |
| Comparing with the product used in the past, the tested product was assessed as better. | 43% | positive responses |
| Intention of buying the product.                                                        | 50% | positive responses |
| Recommendation for a friend.                                                            | 67% | positive responses |

Answers on all questions are presented in the Appendix **8.2**.

## 6.4 Instrumental test results

### 6.4.1 Instrumental test of biomechanical skin parameter by using Cutometer® MPA 580

Assumption:

The product improves skin elasticity, when the parameter value increases.

The product improves skin firmness, when the parameter value decreases.

Table 4. Cutometer® MPA 580. The mean results of skin elasticity (R2 parameter) obtained from measurements before (D0) and after 90 days (D90) of regular use.

| Subject's no.                          | Before (D0) | After 90 days (D90) | Difference (D90-D0) |
|----------------------------------------|-------------|---------------------|---------------------|
| 1.                                     | 0,876       | 0,896               | 0,020               |
| 2.                                     | 0,844       | 0,919               | 0,075               |
| (3.)*                                  | (0,880)*    | UN                  |                     |
| 4.                                     | 0,883       | 0,932               | 0,049               |
| 5.                                     | 0,830       | 0,844               | 0,014               |
| 6.                                     | 0,875       | 0,916               | 0,041               |
| 7.                                     | 0,907       | 0,922               | 0,015               |
| 8.                                     | 0,787       | 0,851               | 0,064               |
| 9.                                     | 0,829       | 0,922               | 0,092               |
| 10.                                    | 0,915       | 0,917               | 0,002               |
| (11.)*                                 | (0,922)*    | UN                  |                     |
| 12.                                    | 0,780       | 0,747               | -0,033              |
| 13.                                    | 0,758       | 0,822               | 0,063               |
| 14.                                    | 0,886       | 0,905               | 0,019               |
| 15.                                    | 0,884       | 0,946               | 0,062               |
| 16.                                    | 0,783       | 0,804               | 0,020               |
| 17.                                    | 0,934       | 0,935               | 0,000               |
| (18.)*                                 | (0,858)*    | UN                  |                     |
| 19.                                    | 0,896       | 0,930               | 0,034               |
| 20.                                    | 0,794       | 0,850               | 0,056               |
| 21.                                    | 0,920       | 0,931               | 0,012               |
| 22.                                    | 0,799       | 0,866               | 0,067               |
| 23.                                    | 0,764       | 0,812               | 0,048               |
| 24.                                    | 0,911       | 0,934               | 0,023               |
| (25.)*                                 | (0,937)*    | UN                  |                     |
| 26.                                    | 0,893       | 0,910               | 0,017               |
| 27.                                    | 0,830       | 0,855               | 0,026               |
| <b>Mean</b>                            | 0,851       | 0,885               | 0,034               |
| <b>Min</b>                             | 0,758       | 0,747               | -0,033              |
| <b>Max</b>                             | 0,934       | 0,946               | 0,092               |
| <b>SD</b>                              | 0,056       | 0,053               | 0,029               |
| <b>Median</b>                          | 0,875       | 0,910               | 0,026               |
| <b>Δ%</b>                              |             |                     | <b>4%</b>           |
| <b>% subjects with positive effect</b> |             |                     | <b>96%</b>          |

Legend:

()\* - The result was not included in the calculation.

UN - untraceable

**REPORT No. 978975-1/25/SLV/GDA/PK**
**MOUNTAINDROP HIMALAYAN SHILAJIT 100G**

Table 5. Cutometer® MPA 580. The mean results of skin firmness (R0 parameter) obtained from measurements before (D0) and after 90 days (D90) of regular use.

| Subject's no.                          | Before (D0) | After 90 days (D90) | Difference (D90-D0) |
|----------------------------------------|-------------|---------------------|---------------------|
| 1.                                     | 0,321       | 0,275               | -0,046              |
| 2.                                     | 0,355       | 0,338               | -0,018              |
| (3.)*                                  | (0,374)*    | UN                  |                     |
| 4.                                     | 0,376       | 0,314               | -0,062              |
| 5.                                     | 0,414       | 0,339               | -0,076              |
| 6.                                     | 0,335       | 0,319               | -0,016              |
| 7.                                     | 0,647       | 0,634               | -0,013              |
| 8.                                     | 0,266       | 0,255               | -0,011              |
| 9.                                     | 0,435       | 0,410               | -0,025              |
| 10.                                    | 0,299       | 0,280               | -0,019              |
| (11.)*                                 | (0,341)*    | UN                  |                     |
| 12.                                    | 0,481       | 0,414               | -0,067              |
| 13.                                    | 0,210       | 0,200               | -0,010              |
| 14.                                    | 0,170       | 0,171               | 0,001               |
| 15.                                    | 0,366       | 0,352               | -0,014              |
| 16.                                    | 0,402       | 0,379               | -0,023              |
| 17.                                    | 0,353       | 0,323               | -0,029              |
| (18.)*                                 | (0,305)*    | UN                  |                     |
| 19.                                    | 0,288       | 0,269               | -0,019              |
| 20.                                    | 0,222       | 0,203               | -0,019              |
| 21.                                    | 0,314       | 0,301               | -0,013              |
| 22.                                    | 0,421       | 0,380               | -0,041              |
| 23.                                    | 0,384       | 0,355               | -0,029              |
| 24.                                    | 0,212       | 0,209               | -0,002              |
| (25.)*                                 | (0,309)*    | UN                  |                     |
| 26.                                    | 0,349       | 0,305               | -0,044              |
| 27.                                    | 0,299       | 0,286               | -0,013              |
| <b>Mean</b>                            | 0,344       | 0,318               | -0,026              |
| <b>Min</b>                             | 0,170       | 0,171               | -0,076              |
| <b>Max</b>                             | 0,647       | 0,634               | 0,001               |
| <b>SD</b>                              | 0,103       | 0,095               | 0,020               |
| <b>Median</b>                          | 0,349       | 0,314               | -0,019              |
| <b>Δ%</b>                              |             |                     | <b>-8%</b>          |
| <b>% subjects with positive effect</b> |             |                     | <b>96%</b>          |

Legend:

()\* - The result was not included in the calculation.

UN - untraceable

**Conclusion:** The product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** improves skin elasticity and skin firmness after 90 days of regular use.

**6.4.2 Instrumental test of hair density using Aramo ASW® 300F**
Assumption:

The product improves hair density when the parameter value increases.

Table 6. Aramo ASW® 300F. Average results of hair density obtained from measurements before (D0) and after 90 days (D90) of regular use in [average amount of hair/cm²].

| Subject's no.                          | Before (D0)  | After 90 days (D90) | Difference (D90-D0) |
|----------------------------------------|--------------|---------------------|---------------------|
| 1.                                     | 141,7        | 151,7               | 10,0                |
| 2.                                     | 115,0        | 125,0               | 10,0                |
| (3.)*                                  | (145,)*      | UN                  |                     |
| 4.                                     | 198,3        | 205,0               | 6,7                 |
| 5.                                     | 113,3        | 126,7               | 13,3                |
| 6.                                     | 171,7        | 185,0               | 13,3                |
| 7.                                     | 125,0        | 138,3               | 13,3                |
| 8.                                     | 121,7        | 136,7               | 15,0                |
| 9.                                     | 145,0        | 158,3               | 13,3                |
| 10.                                    | 145,0        | 161,7               | 16,7                |
| (11.)*                                 | (173,3)*     | UN                  |                     |
| 12.                                    | 108,3        | 123,3               | 15,0                |
| 13.                                    | 113,3        | 123,3               | 10,0                |
| 14.                                    | 196,7        | 213,3               | 16,7                |
| 15.                                    | 126,7        | 143,3               | 16,7                |
| 16.                                    | 148,3        | 163,3               | 15,0                |
| 17.                                    | 118,3        | 131,7               | 13,3                |
| (18.)*                                 | (120,0)*     | UN                  |                     |
| 19.                                    | 108,3        | 121,7               | 13,3                |
| 20.                                    | 141,7        | 151,7               | 10,0                |
| 21.                                    | 118,3        | 130,0               | 11,7                |
| 22.                                    | 116,7        | 126,7               | 10,0                |
| 23.                                    | 138,3        | 150,0               | 11,7                |
| 24.                                    | 103,3        | 116,7               | 13,3                |
| (25.)*                                 | (118,3)*     | UN                  |                     |
| 26.                                    | 163,3        | 168,3               | 5,0                 |
| 27.                                    | 146,7        | 160,0               | 13,3                |
| <b>Mean</b>                            | <b>135,9</b> | <b>148,3</b>        | <b>12,5</b>         |
| <b>Min</b>                             | <b>103,3</b> | <b>116,7</b>        | <b>5,0</b>          |
| <b>Max</b>                             | <b>198,3</b> | <b>213,3</b>        | <b>16,7</b>         |
| <b>SD</b>                              | <b>26,6</b>  | <b>26,3</b>         | <b>3,0</b>          |
| <b>Median</b>                          | <b>126,7</b> | <b>143,3</b>        | <b>13,3</b>         |
| <b>Δ%</b>                              |              |                     | <b>9%</b>           |
| <b>% subjects with positive effect</b> |              |                     | <b>100%</b>         |

Legend:

()\* - The result was not included in the calculation.

UN – untraceable

Conclusion: The product **MOUNTAINDROP HIMALAYAN SHILAJIT 100G** improves hair density after 90 days of regular use.

**7. CONCLUSION**

Under these study conditions, after 90 days of regular use it is concluded, that the product **BEAUTYLLAGEN®**:

- was tested under internist supervision,
- was clinically tested,
- was used by:
  - 33 subjects - internist supervision + use test (30 subjects completed the study),
  - 27 subjects – instrumental test (23 subjects completed this study);
- was used once a day,
- was very well tolerated by subjects,
- properties declared by the Client have been confirmed basing on a subjective questionnaire:
  - The product visibly improves skin elasticity.
  - The product gives the feeling of hydration.
  - The product reduces the appearance of wrinkles.
  - The product visibly improves hair and nail growth.
  - The product visibly increases hair density and nail strength.
  - The product visibly reduces hair loss.
  - The product appears to improve physical energy.
  - The product appears to reduce fatigue.
  - The product appears to increase endurance.
  - The product seems to improve concentrations and mental clarity.
  - The product seems to reduce "brain fog" (increased concentrations).
  - The product seems to reduce stress.
  - The product seems to speed up recovery from exercise.
  - The product seems to improve sleep quality (a greater sense of restfulness is reported).
  - The product seems to maintain good skin condition.
  - The product seems to increase overall vitality.
  - The product seems to improve libido.
- properties declared by the Client have been confirmed basing on instrumental tests:
  - improves skin elasticity (average 4%) and skin firmness (average 8%),
  - improves hair density (average 9%).

## 8. APPENDIX

### 8.1 Internist's scores – individual results

| Internist's evaluation           |                       |             |                        |             |                    |             |                   |             |
|----------------------------------|-----------------------|-------------|------------------------|-------------|--------------------|-------------|-------------------|-------------|
| Evaluation of problem indicators |                       |             |                        |             |                    |             |                   |             |
| Subject's no.                    | General health issues |             | Mild or severe fatigue |             | Digestive problems |             | Slowed metabolism |             |
|                                  | BEFORE (D0)           | AFTER (D90) | BEFORE (D0)            | AFTER (D90) | BEFORE (D0)        | AFTER (D90) | BEFORE (D0)       | AFTER (D90) |
| 1.                               | 0                     | 0           | 1                      | 1           | 1                  | 0           | 1                 | 0           |
| 2.                               | 1                     | 0           | 1                      | 1           | 2                  | 2           | 2                 | 0           |
| 3.                               | 0                     | UN          | 0                      | UN          | 1                  | UN          | 0                 | UN          |
| 4.                               | 2                     | 0           | 3                      | 2           | 1                  | 0           | 1                 | 0           |
| 5.                               | 0                     | 0           | 1                      | 1           | 1                  | 0           | 1                 | 0           |
| 6.                               | 0                     | 0           | 1                      | 0           | 0                  | 0           | 0                 | 0           |
| 7.                               | 0                     | 0           | 2                      | 1           | 2                  | 2           | 0                 | 0           |
| 8.                               | 0                     | 0           | 1                      | 1           | 0                  | 0           | 1                 | 0           |
| 9.                               | 0                     | 0           | 2                      | 0           | 0                  | 0           | 0                 | 0           |
| 10.                              | 1                     | 1           | 2                      | 1           | 1                  | 0           | 2                 | 0           |
| 11.                              | 0                     | UN          | 0                      | UN          | 0                  | UN          | 0                 | UN          |
| 12.                              | 0                     | 0           | 1                      | 1           | 0                  | 0           | 1                 | 0           |
| 13.                              | 0                     | 1           | 2                      | 2           | 2                  | 0           | 1                 | 1           |
| 14.                              | 2                     | 1           | 2                      | 1           | 2                  | 3           | 0                 | 0           |
| 15.                              | 0                     | 0           | 1                      | 0           | 1                  | 0           | 0                 | 0           |
| 16.                              | 0                     | 0           | 2                      | 1           | 0                  | 0           | 0                 | 0           |
| 17.                              | 1                     | 0           | 1                      | 0           | 2                  | 0           | 1                 | 0           |
| 18.                              | 0                     | UN          | 0                      | UN          | 0                  | UN          | 0                 | UN          |
| 19.                              | 0                     | 1           | 0                      | 2           | 0                  | 1           | 0                 | 0           |
| 20.                              | 0                     | 0           | 3                      | 0           | 1                  | 0           | 0                 | 0           |
| 21.                              | 0                     | 0           | 2                      | 2           | 0                  | 0           | 0                 | 0           |
| 22.                              | 0                     | 0           | 1                      | 0           | 0                  | 0           | 0                 | 0           |
| 23.                              | 0                     | 0           | 1                      | 0           | 0                  | 0           | 0                 | 0           |
| 24.                              | 0                     | 0           | 0                      | 0           | 0                  | 0           | 0                 | 0           |
| 25.                              | 0                     | 0           | 2                      | 0           | 2                  | 0           | 0                 | 0           |
| 26.                              | 0                     | 0           | 1                      | 0           | 0                  | 0           | 0                 | 0           |
| 27.                              | 0                     | 1           | 1                      | 1           | 1                  | 0           | 1                 | 0           |
| 28.                              | 1                     | 0           | 0                      | 0           | 0                  | 0           | 0                 | 0           |
| 29.                              | 0                     | 1           | 1                      | 2           | 1                  | 1           | 2                 | 0           |
| 30.                              | 0                     | 0           | 1                      | 1           | 0                  | 0           | 0                 | 0           |
| 31.                              | 0                     | 0           | 2                      | 2           | 1                  | 0           | 0                 | 0           |
| 32.                              | 0                     | 2           | 1                      | 1           | 0                  | 0           | 0                 | 0           |
| 33.                              | 0                     | 0           | 0                      | 1           | 1                  | 0           | 0                 | 0           |
| MEAN                             | 0,2                   | 0,3         | 1,2                    | 0,8         | 0,7                | 0,3         | 0,4               | 0,0         |
| MIN                              | 0,0                   | 0,0         | 0,0                    | 0,0         | 0,0                | 0,0         | 0,0               | 0,0         |
| MAX                              | 2,0                   | 2,0         | 3,0                    | 2,0         | 2,0                | 3,0         | 2,0               | 1,0         |
| SD                               | 0,6                   | 0,5         | 0,8                    | 0,7         | 0,8                | 0,7         | 0,7               | 0,2         |
| MEDIAN                           | 0,0                   | 0,0         | 1,0                    | 1,0         | 1,0                | 0,0         | 0,0               | 0,0         |

Legend:

0 – none

1 – mild

2 – moderate

3 – severe

4 – extremely severe



UN - untraceable

## 8.2 Summary of the questionnaire

One subject presents 3,3%. Values are rounded off.

| 978975-1/25/SLV/GDA/PK                                                                                                                     |                                     |                          |                                                   |                      |                                 |               |
|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------|---------------------------------------------------|----------------------|---------------------------------|---------------|
| I. ASSESSMENT OF THE PRODUCT'S PROPERTIES                                                                                                  |                                     |                          |                                                   |                      |                                 |               |
|                                                                                                                                            | definitely not suitable             | not suitable             | suitable                                          | definitely suitable  |                                 |               |
| 1 <b>Appearance/functionality</b>                                                                                                          | 3%                                  | 13%                      | 70%                                               | 13%                  |                                 |               |
| 2 <b>Consistency</b>                                                                                                                       | 7%                                  | 30%                      | 50%                                               | 13%                  |                                 |               |
| 3 <b>Application</b>                                                                                                                       | 3%                                  | 7%                       | 77%                                               | 13%                  |                                 |               |
| II. MARKETING ASSESSMENT                                                                                                                   |                                     |                          |                                                   |                      |                                 |               |
|                                                                                                                                            | definitely no                       | no                       | yes                                               | definitely yes       |                                 |               |
| 4 <b>The product visibly improves skin elasticity.</b>                                                                                     | 0%                                  | 13%                      | 83%                                               | 3%                   |                                 |               |
| 5 <b>The product gives the feeling of hydration.</b>                                                                                       | 0%                                  | 23%                      | 73%                                               | 3%                   |                                 |               |
| 6 <b>The product reduces the appearance of wrinkles.</b>                                                                                   | 3%                                  | 43%                      | 50%                                               | 3%                   |                                 |               |
| 7 <b>The product visibly improves hair and nail growth.</b>                                                                                | 0%                                  | 27%                      | 67%                                               | 7%                   |                                 |               |
| 8 <b>The product visibly increases hair density and nail strength.</b>                                                                     | 0%                                  | 13%                      | 80%                                               | 7%                   |                                 |               |
| 9 <b>The product visibly reduces hair loss.</b>                                                                                            | 0%                                  | 23%                      | 70%                                               | 7%                   |                                 |               |
| 10 <b>The product appears to improve physical energy.</b>                                                                                  | 0%                                  | 13%                      | 70%                                               | 17%                  |                                 |               |
| 11 <b>The product appears to reduce fatigue.</b>                                                                                           | 0%                                  | 13%                      | 63%                                               | 23%                  |                                 |               |
| 12 <b>The product appears to increase endurance.</b>                                                                                       | 0%                                  | 27%                      | 60%                                               | 13%                  |                                 |               |
| 13 <b>The product seems to improve concentrations and mental clarity.</b>                                                                  | 0%                                  | 20%                      | 70%                                               | 10%                  |                                 |               |
| 14 <b>The product seems to reduce "brain fog" (increased concentrations).</b>                                                              | 0%                                  | 17%                      | 67%                                               | 17%                  |                                 |               |
| 15 <b>The product seems to reduce stress.</b>                                                                                              | 0%                                  | 20%                      | 70%                                               | 10%                  |                                 |               |
| 16 <b>The product seems to speed up recovery from exercise.</b>                                                                            | 0%                                  | 23%                      | 63%                                               | 13%                  |                                 |               |
| 17 <b>The product seems to improve sleep quality (I feel more rested).</b>                                                                 | 0%                                  | 7%                       | 80%                                               | 13%                  |                                 |               |
| 18 <b>The product seems to maintain good skin condition.</b>                                                                               | 0%                                  | 13%                      | 80%                                               | 7%                   |                                 |               |
| 19 <b>The product seems to increase overall vitality.</b>                                                                                  | 0%                                  | 13%                      | 70%                                               | 17%                  |                                 |               |
| 20 <b>The product seems to improve libido.</b>                                                                                             | 3%                                  | 30%                      | 57%                                               | 10%                  |                                 |               |
| III. MARKETING ANALYSIS                                                                                                                    |                                     |                          |                                                   |                      |                                 |               |
|                                                                                                                                            | i definitely do not like it         | i do not like it         | neutral                                           | i like it            | i definitely like it            |               |
| 21 <b>Overall assessment of the product</b>                                                                                                | 0%                                  | 3%                       | 27%                                               | 60%                  | 10%                             |               |
|                                                                                                                                            | definitely worse                    | worse                    | comparable                                        | better               | definitely better               | no comparison |
| 22 <b>Product assessment in comparison with the same type of products used before</b>                                                      | 0%                                  | 3%                       | 33%                                               | 30%                  | 13%                             | 20%           |
|                                                                                                                                            | i definitely would not buy it       | i would not buy it       | i do not know whether i would buy it or not       | i would buy it       | i definitely would buy it       |               |
| 23 <b>Taking under consideration previously tested properties of the products, what is the probability that you will buy this product?</b> | 3%                                  | 13%                      | 33%                                               | 43%                  | 7%                              |               |
|                                                                                                                                            | i would definitely not recommend it | i would not recommend it | i do not know whether i would recommend it or not | i would recommend it | i would definitely recommend it |               |
| 24 <b>Would you recommend this product to a friend?</b>                                                                                    | 0%                                  | 0%                       | 33%                                               | 57%                  | 10%                             |               |

**9. SIGNATURES**

|                            |                                                                                                 |                                                                                                                                           |
|----------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Project Manager:           | <b>Marta Sadowska</b><br><b>Project Manager</b>                                                 | Sign and date<br><br>24.04.2026                        |
| Data Analyst:              | <b>Karolina Wodka-Suchocka</b><br><b>Cosmetic Products Research</b><br><b>Senior Specialist</b> | Sign and date<br><br>24.04.2026                         |
| Quality Assurance Auditor: | <b>Magdalena Lewandowska,</b><br><b>Cosmetic Products Research</b><br><b>Expert</b>             | Sign and date<br><br>24.04.2026                         |
| Internist:                 | <b>Dorota Polańska - Tamborek</b><br><b>(Internal Medicine Doctor)</b><br><b>1175865</b>        | Sign and date<br><br>24.04.2026 Registered N° 1175865 |

Authorized by: Marta Sadowska, Project Manager, (qualified electronic signature)  
Dorota Polańska - Tamborek, Internal Medicine Doctor 1175865

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory: ul. Bajana 3D, 80-463 Gdańsk, Poland

The results relate to the analysed samples only.

This Report cannot be reproduced partially without a prior written consent of J.S. Hamilton Poland Sp. z o.o. Responsibility of J.S. Hamilton Poland Sp. z o.o. is restricted exclusively to the results and statements presented in original copy of the Report. The service confirmed by this Report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on [www.hamilton.com.pl](http://www.hamilton.com.pl)

---

**THE END OF THE REPORT**